SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

MicroCloud Hologram, Inc. engages in research, development, and application of holographic technology. It operates through the Holographic Solutions and Holographic Technology Service segments. The company was founded in 2020 and is headquartered in New York, NY.

MicroCloud Hologram Inc

MicroCloud Hologram is gaining attention, with discussions centering on its potential in quantum computing, AI, and crypto. Bullish sentiment is fueled by reported cash reserves and the possibility of a short squeeze, though some are wary of potential dilution. Recent news and speculation about partnerships are also contributing to the stock's trending status.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance (BETR) is trending due to a hedge fund manager highlighting its potential as a "350-bagger," drawing comparisons to Shopify and Opendoor. The community is actively discussing whether the recent surge is sustainable, with some speculating about a pump-and-dump scheme while others anticipate significant growth from potential interest rate cuts and AI advancements in the mortgage industry and how it affects the company's existing partnership with Opendoor. Additionally, the impact of Eric Jackson's endorsement is a hot topic, with many referencing his previous promotion of Opendoor and questioning his influence.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Disney is trending amid community discussion surrounding the return of Jimmy Kimmel's show after a brief suspension, sparking debates about free speech and political bias. Some subscribers are canceling memberships in protest, while others are defending Disney's decision. The controversy is raising broader questions about Disney's brand image and its appeal to different audience segments.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is trending as investors react to news of the company expanding its focus to high-performance computing (HPC) and AI, in addition to Bitcoin mining. Community members view the stock as undervalued compared to its peers, anticipating a potential revaluation and upward momentum. Some traders point to a large short position, suggesting a possible short squeeze could further drive the price.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors speculate about potential hyperscaler deals and its connection to Nvidia's AI initiatives, fueled by strong price action and high short interest. The community is actively discussing potential partnerships, AI infrastructure demand, and short squeeze setups. Some traders are pointing to the secured contracts and future AI infrastructure demand.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE.X is trending with community members expressing bullish sentiment and excitement. The coin is being associated with the "Rage Guy" meme, while traders are using aggressive language to express their enthusiasm. Some users are discussing potential upward price movement and comparing it to related symbols.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending due to discussions surrounding President Trump's upcoming announcement potentially linking acetaminophen (Tylenol) use during pregnancy to autism, despite the company's denial of a causal link and existing scientific studies. The community is debating the validity of the claims, the potential impact on sales, and possible legal ramifications, with some seeing a buying opportunity amidst the uncertainty. Broader market context includes the stock's YTD performance and analyst ratings.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

MBX Biosciences Inc.

MBX Biosciences is trending due to a proposed public offering of 10 million shares, sparking community discussion around potential dilution. While some investors express concerns about the offering's impact, others view it as a strategic move to strengthen the company's cash position given recent Phase 2 data and a high analyst price target.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

BKKT is trending amid excitement surrounding the appointment of Mike Alfred to the board, with the community buzzing about his potential to drive growth and boost the company's position in the fintech and crypto space. Community members are also focused on the company's debt and expansion into new markets, particularly Japan. However, the stock also faces skepticism with many questioning its long-term viability and expressing concerns about dilution.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about its future growth potential, Elevidys sales, and potential analyst upgrades. Community members are actively debating the impact of recent events on the stock's valuation, with some speculating about a potential acquisition while others focus on upcoming earnings and pipeline catalysts. Concerns about short interest, the FDA, and revenue from Elevidys are also driving conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Kenvue slumped 6% on Monday afternoon following reports that the Trump administration is expected to unveil efforts exploring how Tylenol's active ingredient may be linked to autism.The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.washingtonpost.com/health/2025/09/21/trump-autism-announcement-tylenol-leucovorin/">reported</a> on Monday, citing four people familiar with the matter, that federal health officials are expected to raise concerns about pregnant women using acetaminophen, the active ingredient in Tylenol. They plan to warn pregnant women against using Tylenol early or unless they have a fever, sources told WSJ.Officials also intend to tout a drug called Leucovorin as a potential autism treatment, the report said. Leucovorin is a prescription medication typically used in cancer treatment to counter the harmful side effects of other drugs.White House press secretary Karoline Leavitt, however, urged people to await an announcement today from President Trump at a press briefing.“...before you jump to conclusions based on reports that the White House has not even confirmed, I would encourage everyone in this room to go into the four o'clock announcement with some critical thinking skills and with some open ears to actually listen to what the President and his team of outsiders have to say about this. And there will be a number of things that will be announced and discussed,” she said.Tylenol is made by McNeil Consumer Healthcare, a division of Kenvue, though other companies also sell acetaminophen-based products. It is widely used as a pain reliever, including by pregnant women.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KVUE">KVUE stock</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:574/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_2_12_39_PM_png_4b40cf5a25.webp" alt="KVUE's Sentiment Meter and Message Volume as of 2:12 p.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="574" height="61"><figcaption>KVUE's Sentiment Meter and Message Volume as of 2:12 p.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>Trump, speaking at a memorial for conservative activist Charlie Kirk on Sunday, also touted a big announcement pertaining to autism. “Tomorrow we’re going to have one of the biggest announcement[s] … medically, I think, in the history of our country,” he said, as reported by WSJ. “I think you’re going to find it to be amazing. I think we found an answer to autism.”Earlier this month, it was reported that Kenvue Inc. reportedly <a href="https://stocktwits.com/news-articles/markets/equity/tylenol-kenvue-met-rfk-jr-to-keep-off-autism-list/chw8MshRdDV">met</a> with the U.S. Health Secretary Robert F. Kennedy Jr. in a bid to keep the over-the-counter painkiller off a list of treatments causing autism.“We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” Kenvue <a href="https://stocktwits.com/news-articles/markets/equity/kenvue-jnj-retail-traders-cautious-as-health-officials-plan-to-announce-tylenol-links-to-autism/chDQOxLR3cI">told</a> WSJ in a statement. Autism spectrum disorder (ASD) is a complex developmental condition involving persistent challenges with social communication, restricted interests, and repetitive behavior.KVUE stock is down by 20% this year and by about 25% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-awarded-with-yet-another-price-target-hike-after-waymo-partnership/chDQu3aR32s">Lyft Awarded With Yet Another Price Target Hike After Waymo Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Kenvue logo is seen displayed on a smartphone screen. U.S. health officials will hold a press conference on autism, which is expected to link Kenvue's Tylenol to the disease. (Illustration by Thomas Fuller/Getty Images)

Kenvue Shares Drop Ahead Of Trump’s ‘Biggest Announcement’ On Autism: Reports Say Administration To Link Tylenol With Risk Of Disease

The Wall Street Journal reported on Monday, citing four people familiar with the matter, that federal health officials are expected to raise concerns about pregnant women using acetaminophen, the active ingredient in Tylenol.

Equity

The Wall Street Journal reported on Monday, citing four people familiar with the matter, that federal health officials are expected to raise concerns about pregnant women using acetaminophen, the active ingredient in Tylenol.


The U.S. government is widely expected to link Tylenol to autism, advising pregnant women against its use, Monday, according to media reports. The development is keeping retail investors on the edge for its maker, Kenvue, and associated company Johnson &amp; Johnson, according to Stocktwits data.Tylenol is an acetaminophen-based over-the-counter medicine for reducing pain, allergies, cold, and fever. The popular tablets are produced, marketed, and sold by Kenvue, which spun off from J&amp;J in 2023,&nbsp;and rake in about $1 billion annually, a high-single-digit percentage of the firm’s total revenue,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.morningstar.com/stocks/kenvue-stock-tumbles-kennedys-pending-report-tylenol-autism">according</a> to a Morningstar analyst.U.S. officials&nbsp;are expected to hold a press conference on autism on Monday; in the run-up, President Donald Trump had said: "We think we found an answer to autism... There's obviously something really wrong, we think we know what that is."The Washington Post reported on the weekend that officials will promote the drug leucovorin as a potential autism treatment. Leucovorin is a prescription medication typically used in cancer treatment to counter the harmful side effects of other drugs.Earlier this month, the Wall Street Journal reported U.S. health officials' internal view regarding Tylenol. The news sent Kenvue's shares down 9.4% on Sept. 5. Kenvue said on Sunday that "independent, sound science" shows taking acetaminophen does not cause autism."We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers," the company said in a statement.Several Stocktwits users, on both Kenvue and J&amp;J&nbsp;streams, predicted steep declines for the stocks on Monday. Twenty-four-hour message volume on the tickers surging 300% and 150%, respectively.Retail sentiment for both KVUE and JNJ was ‘neutral’ at the time of writing, indicating significant levels of caution among traders ahead of Monday’s market open.<figure class="image"><img style="aspect-ratio:567/71;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_9_41_57_AM_png_e493de6988.webp" alt="Screenshot 2025-09-22 at 9.41.57 AM.png" width="567" height="71"><figcaption>KVUE sentiment and message volume as of September 21 | Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:571/73;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_9_42_37_AM_png_11ece70092.webp" alt="Screenshot 2025-09-22 at 9.42.37 AM.png" width="571" height="73"><figcaption>JNJ sentiment and message volume as of September 21 | Source: Stocktwits</figcaption></figure>"$JNJ 5-year chart looks like a heartbeat… she's gonna drop and flatline tomorrow," said a user.<stembedurl>https://stocktwits.com/TheDude5386/message/629455153</stembedurl>Another said: "$KVUE could be a buying opportunity if we see an overreaction."<stembedurl>https://stocktwits.com/Sigh_why/message/629453593</stembedurl>Kenvue's main brands include Tylenol, Motrin, Listerine, Neutrogena, Aveeno, and Band-Aid.<a href="https://stocktwits.com/symbol/KVUE">Kenvue shares</a> are down 14.1% year-to-date;&nbsp;<a href="https://stocktwits.com/symbol/JNJ">J&amp;J stock</a> is up 22%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-confirms-news-corp-s-murdochs-larry-ellison-michael-dell-lining-up-to-take-over-tik-tok-us/chDQBrbR3cR">Trump Confirms News Corp’s Murdochs, Larry Ellison, Michael Dell Lining Up To Take Over TikTok US</a>

Pain medications, which contain acetaminophen, are shown on April 14, 2015 in Chicago, Illinois. (Photo Illustration by Scott Olson/Getty Images)

Kenvue, J&J Retail Traders Cautious As US Health Officials Reportedly Plan To Announce Tylenol Links To Autism

Tylenol is one of the most common medicines for reducing pain and fever, and a major product for Kenvue.

Top Wide-Moat Stocks Worth a Look for Sustainable Growth 

MSFT, JNJ, NKE and SPGI use strong moats to fend off rivals and deliver consistent returns amid market shifts.

Tylenol maker Kenvue Inc. (KVUE) reportedly met with the U.S. Health Secretary Robert F. Kennedy Jr. in a bid to keep the over-the-counter painkiller off a list of treatments causing autism.According to a Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-12/kenvue-met-with-rfk-jr-in-bid-to-keep-tylenol-off-autism-list">report</a>, Kenvue confirmed the meeting with RFK Jr., maintaining that acetaminophen, the active ingredient in Tylenol, does not cause autism.<a href="https://stocktwits.com/symbol/KVUE">Kenvue’s shares</a> were up 1.24% in Friday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory.Kenvue said in an emailed statement to Bloomberg that it engaged with the Health Secretary in a “scientific exchange” as it relates to the safety of its products. “We continue to believe that taking acetaminophen does not cause autism, and global health regulators, independent public health organizations, and medical professionals agree,” the company said, adding that acetaminophen is one of the most studied medications in history.Tylenol is a part of Kenvue’s self-care segment, which accounted for more than 40% of the company’s revenue in the second quarter (Q2). The company’s organic sales fell 4.2% during the quarter, which was due to “weak allergy and sun seasons in North America, trade inventory fluctuations in certain customers, and changes in shipment timing versus last year in China,” according to a statement from Kenvue.Last week, a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/rfk-jr-hhs-to-link-autism-to-tylenol-use-in-pregnancy-and-folate-deficiencies-e3acbb4c">report</a> by The Wall Street Journal noted the Department of Health and Human Services could link autism to the use of Tylenol in pregnancy. The HHS report is expected to be issued this month, it added.<a href="https://stocktwits.com/symbol/KVUE">KVUE stock</a> is down 11% year-to-date and 17% in the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-fed-rate-cuts-through-january/chw8AhGRdDi">Morgan Stanley Reportedly Expects 4 Rate Cuts Through January, Says Fed Will Aim To Arrive At Neutral Rates ‘More Decisively’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Kenvue company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Tylenol Maker Kenvue Met With RFK Jr. In A Bid To Keep OTC Painkiller Off Autism List: Report

According to a Bloomberg report, Kenvue confirmed the meeting with RFK Jr., maintaining that acetaminophen, the active ingredient in Tylenol, does not cause autism.

Bank of America stated that Kenvue (KVUE) is expected to be viewed as a “particularly attractive entry point” after the recent pullback in its stock following media reports that surfaced that Health Secretary Robert F. Kennedy Jr. intends to link prenatal use of its Tylenol drug to autism.Analyst Anna Lizzul said that the company's new CEO and CFO took the opportunity in August to reset expectations at earnings and sees its lowered 2025 guidance as "achievable," according to TheFly.Shares of <a href="https://stocktwits.com/symbol/KVUE">Kenvue</a> closed down 9.3% on Friday. Bank of America noted that given the current valuation discount to the average of household and personal care peers, the firm reiterates its ‘Buy’ rating and $25 price target as it sees a widening discount offering an attractive entry point.Retail sentiment on Kenvue dipped to ‘bullish’ from ‘extremely bullish’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:807/107;" src="https://news.stocktwits-cdn.com/KVUE_sentiment_png_2b6f08c92e.webp" alt="KVUE sentiment.png" width="807" height="107"><figcaption>KVUE sentiment and message volume September 8, 2025, as of 8:30 am ET | Source: Stocktwits</figcaption></figure>Evercore ISI lowered its price target on Kenvue to $23 from $25 and maintained an ‘In Line’ rating, reflecting lower peer valuations and the premium Tylenol commands within Kenvue's portfolio. The firm noted that the recent selloff in shares "might be overdone" when considering the lack of a proven causal link between Tylenol's active ingredient and neurodevelopmental disorders.According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/rfk-jr-hhs-to-link-autism-to-tylenol-use-in-pregnancy-and-folate-deficiencies-e3acbb4c">report</a> by The Wall Street Journal, in an upcoming Health Department report, there would be findings expected to link autism risk to low folate levels and Tylenol use during pregnancy.&nbsp;Despite headline risks, a lack of definitive evidence linking Acetaminophen, the active ingredient in Tylenol, to autism may suggest limited long-term impact. Still, legal uncertainties could delay strategic moves, Evercore added.&nbsp;&nbsp;Kenvue shares have declined nearly 13% this year and approximately 20% over the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/this-sportswear-giant-got-added-to-jefferies-franchise-picks-list/chwWxLeRdrc">This Sportswear Giant Got Added To Jefferies’ Franchise Picks List – Find Out More</a>

Kenvue Seen As Attractive Buy By BofA After Stock Dip Following Report On Tylenol Autism Link

Evercore said that the recent selloff in shares "might be overdone" when considering the lack of a proven causal link between Tylenol's active ingredient and neurodevelopmental disorders.

Kenvue Seen As Attractive Buy By BofA After Stock Dip

Tylenol maker Kenvue (KVUE) dropped to a one-year low in afternoon trade on Friday after reports surfaced that Health Secretary Robert F. Kennedy Jr. intends to link prenatal use of the drug to autism.<a href="http://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> tumbled more than&nbsp;13%&nbsp;to&nbsp;$17.77, its lowest level since&nbsp;July 2024. On Stocktwits, retail sentiment around the company fell into ‘bearish’ territory from ‘neutral’ over the past day.&nbsp;Friday’s drop brings Kenvue’s year-to-date loss to over 17%. The stock has fallen 21% over the past 12 months.According to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/rfk-jr-hhs-to-link-autism-to-tylenol-use-in-pregnancy-and-folate-deficiencies-e3acbb4c">report</a> by The Wall Street Journal, the Department of Health and Human Services (HHS) is likely to release its findings later this month. The upcoming Health Department report is expected to link autism risk to low folate levels and Tylenol use during pregnancy, people familiar with the matter told the publication.Tylenol is made by McNeil Consumer Healthcare, a division of Kenvue, though other companies also sell acetaminophen-based products. The active ingredient in Tylenol is acetaminophen, which is widely used as a pain reliever, including by pregnant women.&nbsp;The report said that research on its impact during pregnancy has produced mixed results. It cited that the American College of Obstetricians and Gynecologists found Tylenol to be safe for use during pregnancy. However, it advises women to consult with their doctors before taking any medication.Kennedy, meanwhile, has long promised to reveal the cause of autism. “By September, we will know what has caused the autism epidemic,” he&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bbc.com/news/articles/cj0z9nmzvdlo">said</a> during an April cabinet meeting with President Donald Trump.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bessent-says-fed-must-change-course-to-preserve-independence/chwI13sRdqQ">Bessent Reportedly Says Fed Must Change Course To Preserve Independence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tylenol, which contains acetaminophen, is offered for sale at a drug store on April 14, 2015 in Chicago, Illinois. (Photo by Scott Olson/Getty Images)

Kenvue Stock Hits One-Year Low After Report Says HHS Will Link Tylenol Use In Pregnancy To Autism Risk

According to a report by The Wall Street Journal, the Department of Health and Human Services is likely to release its findings later this month. 

J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?

Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.

Kenvue (KVUE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Kenvue (KVUE) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Kenvue (KVUE) Q2 Earnings Top Estimates

Kenvue (KVUE) delivered earnings and revenue surprises of +3.57% and -0.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Edgewell Personal Care (EPC) Misses Q3 Earnings and Revenue Estimates

Edgewell Personal (EPC) delivered earnings and revenue surprises of -8.91% and -4.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

KVUE
Kenvue Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KVUE News

KVUE Kenvue Inc